Riskpilot← Back to searchSign inGet full accessBetaMed AB
ABActiveOrg 5566611090Fiskebergsvägen 6Research and experimental development on natural sciences and engineering · NACE 7210Est. 20041-4 employees
Revenue 2025
SEK 191K
-16% vs 2024
EBITDA margin
-16.2%
-261% vs 2024
Equity ratio
43.1%
Financial strength
Net profit 2025
SEK -31K
-295% vs 2024
| Revenue | SEK 191K | -16% |
| EBITDA | SEK -31K | -261% |
| Net profit | SEK -31K | -295% |
| Total assets | SEK 246K | -6% |
| Equity | SEK 106K | -23% |
| Employees | — | — |
Legal name
BetaMed AB
Org number
5566611090
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
22 april 2004
Share capital
SEK 100 000
Employees
1-4
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas ensam av Hanås, Sven Ragnar
Company purpose
Föremålet för bolagets verksamhet är medicinsk information, utbildning och forskning samt förlagsverksamhet inom medicin, natur och fritidsverksamhet, varuhandel inom natur och fritidverksamhet och därmed förenlig verksamhet.
Address
Fiskebergsvägen 6
Phone
+46304671229
Email
ragnar.hanas@betamed.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 335 | 245 | 277 | 227 | 191 |
| Staff expenses | — | −3 | −2 | −59 | −27 |
| EBITDA | 104 | 43 | 33 | 19 | −31 |
| Depreciation & amort. | −6 | −6 | −6 | — | — |
| EBIT | 98 | 37 | 28 | 19 | −31 |
| Net financials | — | −0 | −0 | 1 | 0 |
| Profit before tax | 98 | 37 | 27 | 20 | −31 |
| Tax | −21 | −12 | −7 | −4 | — |
| Net profit | 77 | 25 | 21 | 16 | −31 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 351 | 217 | 239 | 261 | 246 |
| Equity | 196 | 146 | 142 | 137 | 106 |
| Long-term debt | 0 | — | — | — | — |
| Short-term debt | 156 | 71 | 97 | 124 | 140 |
| Total debt | 156 | 71 | 97 | 124 | 140 |
EBITDA margin
-16.2%
This company
15.8%
Market median
-203% vs market
20212025
Equity ratio
43.1%
This company
38.2%
Market median
+13% vs market
20212025
Return on equity
-29.2%
This company
18.4%
Market median
-259% vs market
20212025
Net profit margin
-16.2%
This company
8.1%
Market median
-300% vs market
20212025
Asset turnover
0.78×
This company
1.12×
Market median
-30% vs market
20212025
Debt / equity
1.32×
This company
0.62×
Market median
-113% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Chairman | 2022 | |
| Board of Directors | 2025 | |
| Deputy Board Member | 2022 | |
| Former (1) | ||
| Board of Directors | 2022 – 2025 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of BetaMed AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Sven Håkan Jansson | Board of Directors | 0 companies |
| Sven Ragnar Hanås | Chairman | 0 companies |
| Karin Elisabet Haby | Board of Directors | 0 companies |
| Malin Cecilia Karin Hanås | Deputy Board Member | 0 companies |